Eribulin – a chemotherapy drug derived from sea sponge – has been found to extend the lives of women with metastatic breast cancer by about 2.5 months.
According to study author Dr. Christopher Twelves, who is a professor of clinical cancer pharmacology and oncology and head of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St. James’ Institute of Oncology in Leeds, U.K.:
“We have a major need for new therapies. We see a statistically significant benefit in overall survival in a situation where we rarely see this sort of improvement. Eribulin targets the . . . mechanisms by which the cells divide, which is different from previous agents.”
The above finding was presented on Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago.